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PLINICAL RESEARCH Clinical Trials
tatins Decrease Perioperative
ardiac Complications in Patients
ndergoing Noncardiac Vascular Surgery
he Statins for Risk Reduction in Surgery (StaRRS) Study
ristin O’Neil-Callahan, MD,† George Katsimaglis, MD,*§ Micah R. Tepper, MD, Jason Ryan, MD,†
arla Mosby, MD,† John P. A. Ioannidis, MD,¶ Peter G. Danias, MD, PHD*†‡
oston, Massachusetts; and Athens and Ioannina, Greece
OBJECTIVES We sought to assess whether statins may decrease cardiac complications in patients
undergoing noncardiac vascular surgery.
BACKGROUND Cardiovascular complications account for considerable morbidity in patients undergoing
noncardiac surgery. Statins decrease cardiac morbidity and mortality in patients with coronary
disease, and the beneficial treatment effect is seen early, before any measurable increase in
coronary artery diameter.
METHODS A retrospective study recorded patient characteristics, past medical history, and admission
medications on all patients undergoing carotid endarterectomy, aortic surgery, or lower
extremity revascularization over a two-year period (January 1999 to December 2000) at a
tertiary referral center. Recorded perioperative complication outcomes included death,
myocardial infarction, ischemia, congestive heart failure, and ventricular tachyarrhythmias
occurring during the index hospitalization. Univariate and multivariate logistic regressions
identified predictors of perioperative cardiac complications and medications that might confer
a protective effect.
RESULTS Complications occurred in 157 of 1,163 eligible hospitalizations and were significantly fewer
in patients receiving statins (9.9%) than in those not receiving statins (16.5%, p 0.001). The
difference was mostly accounted by myocardial ischemia and congestive heart failure. After
adjusting for other significant predictors of perioperative complications (age, gender, type of
surgery, emergent surgery, left ventricular dysfunction, and diabetes mellitus), statins still
conferred a highly significant protective effect (odds ratio 0.52, p  0.001). The protective
effect was similar across diverse patient subgroups and persisted after accounting for the
likelihood of patients to have hypercholesterolemia by considering their propensity to use
statins.
CONCLUSIONS Use of statins was highly protective against perioperative cardiac complications in patients
undergoing vascular surgery in this retrospective study. (J Am Coll Cardiol 2005;45:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.048336–42) © 2005 by the American College of Cardiology Foundation
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sardiac complications of noncardiac surgery account for
onsiderable morbidity and mortality, particularly in pa-
ients with pre-existing coronary artery disease (CAD)
1,2). Although improvements in operative technique and
erioperative management have decreased the overall com-
lication rate, certain types of surgery, such as vascular
urgery, are still associated with a high risk of cardiac
omplications (2). Myocardial infarction (MI) remains the
eading cause of perioperative morbidity and mortality after
ascular surgery (2). With the exception of beta-blockers
3–5), no other pharmacologic therapies have been shown to
From the *Cardiovascular Division and †Department of Medicine, Beth Israel
eaconess Medical Center and Harvard Medical School, Boston, Massachusetts;
Second Cardiology Clinic, Hygeia Hospital, Athens, Greece; §Naval Hospital,
thens, Greece; Institute for Clinical Research and Health Policy Studies, Tufts-
ew England Medical Center, Tufts University School of Medicine, Boston,
assachusetts; and ¶Department of Hygiene and Epidemiology, University of
oannina School of Medicine, Ioannina, Greece.a
Manuscript received September 2, 2004; revised manuscript received October 13,
004, accepted October 18, 2004.ignificantly decrease the risk for perioperative cardiac
omplications.
Inhibitors of the enzyme reductase of the hydroxy-
ethylglutaryl-coenzyme A (HMG-CoA) reductase, or
statins,” have been demonstrated to decrease cardiac events
nd increase survival in patients with hypercholesterolemia
nd either established CAD or at high risk for CAD (6–8).
tatins have also been shown to decrease cardiac events in
atients with CAD and moderately high or normal total or
ow-density lipoprotein serum cholesterol (9–11). Besides
ecreasing cardiac events, statins also decrease the risk of
troke (8,12) and improve lower extremity claudication
8,13,14). Finally, in case-control studies, statins have been
ssociated with lower perioperative (15) and long-term (16)
ortality after major noncardiac vascular surgery. The
eneficial effect of statins is detected very early, long before
ny angiographically measurable regression of atherosclero-
is (17–19). The early beneficial effect in patients with
therosclerosis has been suggested to be due to stabilization
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February 1, 2005:336–42 Statins Reduce Cardiac Events in Vascular Surgeryf the soft lipid-rich atherosclerotic plaque and possibly
mprovement of endothelial function (20–24).
The potential beneficial effect of statins in preventing
erioperative nonfatal and fatal cardiac complications in
atients undergoing noncardiac vascular surgery has not
een adequately assessed. We hypothesized that periopera-
ive therapy with statins may reduce cardiac complications
death, MI, myocardial ischemia, acute congestive heart
ailure, and ventricular tachyarrhythmias) in patients under-
oing noncardiac vascular surgery.
ETHODS
tudy population. We retrospectively identified all pa-
ients who underwent carotid endarterectomy, aortic surgery
aorto-iliac bypass, aneurysm, or dissection repair) or pe-
ipheral lower extremity revascularization not involving the
orta during a two-year period (January 1, 1999, to Decem-
er 31, 2000) at the Beth Israel Deaconess Medical Center,
tertiary referral center. The study was approved by the
ospital Committee on Clinical Investigation.
ata extraction. Medical records were retrieved for all pa-
ients meeting the aforementioned inclusion criteria and re-
arding patient characteristics, and outcomes were extracted
nd recorded on standardized data forms. In particular, data
ere collected from the surgical admission and subsequent
ospital notes, anesthetic preoperative, intraoperative, or post-
perative reports and medicine, cardiology, or other consulta-
ion notes. Data on demographics, past medical history, and
edication use were not independently verified. Six investiga-
ors, including two attending cardiologists (G.K. and P.G.D.)
nd four medical residents (K.O-C., M.R.T., J.R., and C.M.)
erformed the data extraction. In order to validate the inter-
bserver agreement in the data extraction process among the
our medical residents who contributed, a random sample of
% of the records was extracted independently. Data were
ompared with Cohen’s kappa coefficient. Agreement is usu-
lly considered excellent for kappa 0.9 and very good for
appa 0.6 to 0.9. There was excellent agreement on whether
atients were receiving statins or not (kappa 0.96) and very
ood agreement on whether they had an outcome of interest or
ot (kappa 0.78). There was also generally very good agree-
ent on items of past medical history (e.g., CAD kappa 0.89,
I kappa 0.67, left ventricular dysfunction kappa 0.68) and
ther medication use (e.g., beta-blockers kappa 0.82), and
ore modest agreement on the acuity of the operation (kappa
.51). There was no evidence that any data extractor had
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CAD  coronary artery disease
CI  confidence interval
MI  myocardial infarction
OR  odds ratioarticularly higher discrepancy rates than the others. We phould caution that effect estimates for variables with lower
appa coefficients may be less accurate than those for variables
ith higher kappa coefficients, because misclassification is
ore likely in the first group.
utcomes. Outcomes of interest were specified a priori to
nclude the following complications occurring during the
ndex hospitalization (defined as the day of surgery until the
ay of discharge from the hospital): death; acute MI
ocumented according to World Health Organization cri-
eria; myocardial ischemia, defined as angina and/or char-
cteristic electrocardiographic changes (ST-segment de-
ression 1 mm, T-wave peaking, flattening, or inversion
n the absence of electrolyte abnormalities that could be
esponsible for these changes); acute congestive heart failure
documented in the chart as “congestive heart failure,” new
ales, third heart sound, or need for a cardiology consult for
yspnea; postoperative use of diuretics alone was not con-
idered as congestive heart failure); and ventricular tachyar-
hythmias. The time of onset of these complications was
lso recorded (days after surgery). In patients in whom
ultiple outcomes occurred, the most serious outcome (in
rder: death, MI, myocardial ischemia, congestive heart
ailure, ventricular tachyarrhythmia) was considered.
ther collected information. For each case, we also ex-
racted the following information: age, gender, height,
eight, body mass index, type of surgery, acuity of surgery
emergent, urgent, elective), past medical history including
AD, MI, left ventricular dysfunction, hypertension, dia-
etes mellitus, hyperlipidemia (including hypercholesterol-
mia), smoking habits (classified as current smoker [defined
s smoking within the past five years], ex-smoker, and
onsmoker), and the use of medications at the time of
urgery, including statins, beta-blockers, angiotensin-
onverting enzyme (ACE) inhibitors, aspirin, other antili-
id agents, calcium channel blockers, and nitrates.
tatistical analysis. The main objective was to address
hether the use of statins was associated with a reduced risk
f perioperative cardiac complications and whether this
enefit was independent of other candidate predictors of
hese outcomes. We estimated that, assuming that almost
alf of the patients may be receiving statins, in order to have
0% power to detect a 30% reduction in the cardiac
omplication rate, from 15% to 10%, 1,350 hospitaliza-
ions would be required. This was roughly the number of
ases expected to accumulate within a two-year period.
For each one of the parameters that we recorded, we
valuated whether there was an association with the risk of
aving any perioperative cardiac complication during the
ndex hospitalization. We performed univariate logistic
egressions, and parameters with p  0.25 on univariate
nalysis were considered in a multivariate model using
ackward elimination of variables according to likelihood
atio criteria (25). In order to evaluate whether the effect of
tatins might differ across various subgroups, we performed
ubgroup analyses using as grouping factors the other
arameters selected by the multivariate model. Because
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Statins Reduce Cardiac Events in Vascular Surgery February 1, 2005:336–42ome patients had more than one eligible hospitalization
uring the study period (for more than one eligible vascular
perations), we performed additional analyses limited to the
rst eligible hospitalization per patient.
Patients may be selected to use or not use statins based on
arious parameters. Thus, users and nonusers are not sim-
lar, and this is an inherent limitation of a nonrandomized
tudy. One way to try to address this bias is by propensity
nalyses. Propensity analyses aim to identify which are the
mportant parameters that are associated with statin use. A
core is thus calculated that can be used in trying to adjust
he estimates of statin efficacy. Here, the propensity score
as estimated from multivariate logistic regression (26). We
lso evaluated the effect of statins, excluding propensity
core quartiles where the use of statins was either negligible
r almost ubiquitous. The level of statistical significance was
et at p  0.05.
Analyses were conducted in SPSS 11.0 (SPSS Inc.,
hicago, Illinois). All p values are two-tailed.
ESULTS
tudy population. A total of 1,163 hospitalizations on 997
atients were retrieved and included in the study analysis.
he characteristics of the study population are shown in
able 1. Overall, this was an elderly population with a male
able 1. Characteristics of the Study Population
edian (IQR) age (yrs) 71 (63–78)
ale gender 709 (61.0%)
edian (IQR) BMI (kg/m2) 25.8 (23.3–29.8)
ype of surgery
Carotid 364 (31.3%)
Aortic 177 (15.2%)
Lower extremity 622 (53.5%)
cuity of surgery
Emergent 14 (1.2%)
Urgent 176 (15.1%)
Elective 973 (83.7%)
ast medical history
Coronary artery disease 657 (56.5%)
Myocardial infarction 439 (37.7%)
Left ventricular dysfunction 334 (28.7%)
Hypertension 871 (74.9%)
Diabetes melitus 601 (51.7%)
Hyperlipidemia 602 (51.8%)
moking history
Current smoking 304 (26.1%)
Ex-smoker 434 (37.4%)
Never smoked 425 (36.5%)
harmacologic treatment
Statins 526 (45.2%)
Beta-blockers 571 (49.1%)
ACE inhibitors 533 (45.8%)
Aspirin 607 (52.2%)
Other antilipid agents 29 (2.5%)
Calcium channel blockers 311 (26.7%)
Nitrates 185 (15.9%)
ata are presented as the median value (IQR) or number (%) of patients.
ACE  angiotensin-converting enzyme; BMI  body mass index; IQR 
nterquartile range.redominance with considerable past medical history, in- sluding a high prevalence of diabetes, hypertension, and
ardiac disease. Statins, beta-blockers, aspirin, and ACE
nhibitors were given in about half the cases each. The
arge majority of the operations were elective, and slightly
ore than half pertained to the lower extremities. Approx-
mately 60% of the study population were either current or
x-smokers.
omplications. Complications of interest were recorded in
57 hospitalizations, including 52 (9.9%) of the 526 hospi-
alizations where statins were given and 105 (16.5%) of the
37 hospitalizations in patients not receiving statins. This
orresponds to a 6.6% unadjusted difference in the risk of
omplications with statins (number needed to treat  15).
here was no major difference in the relative timing of onset
f complications in patients receiving versus those not
eceiving statins (p  0.94 by the Mann-Whitney U test).
pecifically, 15 versus 10 patients had onset of complica-
ions on the day of surgery and 58 versus 22 patients had
nset of complications within the next two days, and in 33
ersus 20 patients, the complications started later (patients
ithout statins vs. with statins, respectively). The types of
omplications are shown in Table 2. When all complica-
ions were considered, the odds ratio (OR) was 0.56 (95%
onfidence interval [CI] 0.39 to 0.79, p  0.0012), and a
imilar and statistically significant OR estimate was seen for
he combined end point of death, MI, and myocardial
schemia (OR 0.56, 95% CI 0.31 to 0.99, p 0.046). Statin
se was not related to a clear benefit for deaths or MIs, and
he benefit was driven by myocardial ischemia.
ffect of statin use on complications: unadjusted, ad-
usted, and subgroup analyses. Statin use was associated
ith a highly significant reduction in the rate of complica-
ions both on univariate analysis and in the final multivariate
odel that also accounted for age, gender, body mass index,
ype of operation, acuity of operation, left ventricular
ysfunction, and diabetes mellitus (Table 3). The beneficial
ffect of statin use was similar in univariate and adjusted
nalyses. No other pharmacologic intervention was retained
s an independent predictor of the complication rate in the
ultivariate model. In particular, when beta-blockers were
lso considered with forced entry in the multivariate model,
he protective effect of statins remained unchanged (OR
.52, 95% CI 0.35 to 0.77), whereas beta-blockers had no
lear effect (OR 0.96, 95% CI 0.66 to 1.40). An extensive
rray of subgroup analyses (Fig. 1) showed no statistically
able 2. Complication Outcomes
Receiving Statins
(n  52)
Not Receiving Statins
(n  105)
eath 6 5
yocardial infarction 7 7
ther ischemia 5 26
ongestive heart failure 21 50
entricular tachyarrhythmia 13 17
n this table, for patients with more than one of these complications, only the outcome
igher on the list is counted.ignificant differences between any subgroups of interest
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February 1, 2005:336–42 Statins Reduce Cardiac Events in Vascular Surgeryp  0.1 for all subgroup comparisons). The relative
agnitude of the effect was also highly consistent with ORs
anging from 0.43 to 0.66 in all subgroups, with the
xception of a higher OR in patients undergoing emergent
urgery (OR 0.83). The beneficial effect was similar (OR
Table 3. Associations of Various Parameters W
Univariate Logisti
OR (95% CI)
Age, per yr 1.022 (1.005–1.039)
Male gender 0.79 (0.56–1.11)
BMI per kg/m2 1.018 (0.988–1.050)
Type of surgery
Carotid 0.32 (0.20–0.53)
Aortic 1.40 (0.92–2.13)
Lower extremity 1.00 (reference categor
Acuity of surgery
Emergent 5.13 (1.75–15.0)
Urgent 1.25 (0.78–1.99)
Elective 1.00 (reference categor
Past medical history
CAD 1.90 (1.32–2.72)
Myocardial infarction 1.87 (1.34–2.63)
LV dysfunction 4.76 (3.35–6.76)
Hypertension 0.98 (0.66–1.44)
Diabetes mellitus 1.77 (1.25–2.50)
Hyperlipidemia 0.64 (0.45–0.89)
Smoking history
Current smoking 0.55 (0.35–0.86)
Ex-smoker 0.74 (0.51–1.08)
Never smoked 1.00 (reference categor
Pharmacologic treatment
Statins 0.56 (0.39–0.79)
Beta-blockers 1.16 (0.83–1.62)
ACE inhibitors 1.52 (1.08–2.12)
Aspirin 0.94 (0.68–1.32)
Other antilipid agents 1.03 (0.35–2.99)
CCB 0.82 (0.56–1.22)
Nitrates 2.20 (1.49–3.27)
ACE  angiotensin-converting enzyme; BMI  body mass
blockers; CI  confidence interval; LV  left ventricular; O
igure 1. The odds ratio and 95% confidence interval for complications in
atients receiving versus those not receiving statins across subgroupsa
efined by various parameters. BMI  body mass index; LV  left
entricular..55, p  0.002) when only the first hospitalization was
onsidered for each patient.
ropensity for statin use. The use of statins was indepen-
ently associated with a history of hypercholesterolemia
OR 104, p  0.001), CAD (OR 2.06, p  0.001), carotid
urgery (OR 1.49, p  0.069), use of beta-blockers (OR
.75, p  0.008), and higher body mass index (OR 1.051
er 1 kg/m2) and was inversely associated with nonelective
urgery (OR 0.60, p 0.070) and use of other antilipidemic
herapy (OR 0.11, p  0.001). After adjusting for the
erived propensity score, the benefit of statins remained
nchanged (OR 0.49, 95% CI 0.28 to 0.84, p 0.009). The
se of statins was minimal in the lowest quartile of the
ropensity score (1.0%) and was almost ubiquitous in the
ighest quartile of the propensity score (90.3%). Excluding
hese extreme quartiles where statin use would be either
inimal or almost ubiquitous, the use of statins was still
ssociated with a halving of the odds of having a compli-
ation in the remaining two quartiles (OR 0.48, 95% CI 0.2
o 90.80, p  0.005).
ISCUSSION
ur study showed a strong protective effect of statins
the Risk of Complications
lyses Multivariate Logistic Model
p Value OR (95% CI) p Value
0.010 1.023 (1.005–1.041) 0.014
0.18 0.73 (0.50–1.05) 0.092
0.24 1.034 (1.000–1.068) 0.050
0.001 0.55 (0.32–0.93) 0.027
0.12 2.36 (1.41–3.95) 0.001
1.00 (reference category)
0.003 3.71 (1.03–13.4) 0.045
0.35 1.00 (reference category)
1.00 (reference category)
0.001
0.001
0.001 4.55 (3.11–6.65) 0.001
0.91
0.001 1.58 (1.03–2.44) 0.037
0.009
0.009
0.12
0.001 0.52 (0.35–0.76) 0.001
0.40
0.016
0.74
0.96
0.34
0.001
; CAD  coronary artery disease; CCB  calcium channel
odds ratio.ith
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Statins Reduce Cardiac Events in Vascular Surgery February 1, 2005:336–42ndergoing vascular surgery. Overall, one would need to
reat 15 patients with statins to avoid one cardiac compli-
ation, as defined in this study, during the index hospital-
zation. The magnitude of this treatment effect is similar to
ther established pharmacologic interventions for secondary
revention in patients with CAD, including the use of
ntithrombotics, beta-blockers, ACE inhibitors, and statins
7,9,10,27–29). Compared with other parameters that af-
ected the risk of complications in our multivariate model,
he protective effect of statins was not so large as to
ounterbalance strong risk factors such as left ventricular
ysfunction or emergent surgery. However, statin use was
he only pharmacotherapy that remained significant in our
ultivariate model. The relative benefit of statins was
imilar across a large variety of patient subgroups and was
onsistent in unadjusted and adjusted analyses, as well as in
nalyses that took into account the different propensity of
arious patients to use statins. There was no evidence that
he benefit was different in the early versus late postoperative
eriod during the index hospitalization.
There was a suggestion that the benefit pertained mostly
o the incidence of ischemia and congestive heart failure,
lthough there was no apparent reduction in the incidence
f death and MI. The numbers of “hard” end points in our
tudy was relatively small, leading to greater statistical
ncertainty. Alternatively, patients not receiving statins may
e more selected as to closer observation; thus, softer end
oints may have been better detected. The retrospective and
pen, nonrandomized design of our study makes it difficult
o account for the potential of such bias. Nonrandomized
etrospective studies sometimes yield more prominent treat-
ent effects that are not always validated in subsequent
andomized trials (30). We have tried to adjust for a large
ariety of candidate predictors of perioperative cardiac
omplications and also took propensity scoring into account.
t is also unavoidable that some misclassification errors
ight have occurred in the data collection, but the inter-
bserver agreement was very good or even excellent for the
ain variables of interest. Finally, patients with vascular
isease may have several other indications for using statins.
or example, our population was composed of patients with
high prevalence of CAD and hyperlipidemia; thus, it is
ossible that statins were actually underutilized in our
ohort, as compared with standard guideline recommenda-
ions.
The mechanism through which statins confer their pos-
ulated beneficial effect perioperatively is uncertain. Statins
ay have antithrombotic effects unrelated to cholesterol
eduction (31–33) and anti-inflammatory effects through
he downregulation of cytokines (21,23,34). Statins may
lso influence the vascular subcellular milieu to shift vaso-
ctive factors toward vasodilation (22). Finally, in experi-
ental models of MI and heart failure, statins normalized
he sympathetic outflow and reflex regulation and attenu-
ted left ventricular remodeling (35), whereas in humans
ith dilated cardiomyopathy, short-term use of statins is issociated with the improvement of cardiac function and
ymptoms (36,37). Although one can speculate that some or
ll of these mechanisms may be associated with our findings
f improved outcomes in patients undergoing vascular
urgery, the nature of our study does not allow for a
echanistic explanation.
Data on perioperative outcomes in patients receiving
tatins are sparse. Poldermans et al. (15) performed a
ase-control study of 160 fatalities undergoing major vas-
ular surgery at the Erasmus Center during the period 1991
o 2000. The mortality rate in the overall Erasmus cohort
as much higher than the one seen in our study (5.8% vs.
.9%). These investigators demonstrated a large survival
enefit (adjusted OR 0.22) for patients who were receiving
tatins. Our results in a recent cohort with a much lower risk
f death suggest a more conservative estimate of benefit.
nother study by the same group assessing the long-term
urvival of patients surviving abdominal aortic aneurysm
urgery (16) also showed that survival was better for patients
eceiving statins, in accordance with other statin data in
atients with coronary and vascular disease.
In previous studies, beta-blockers have been shown to
ecrease the incidence of perioperative complications in
atients undergoing noncardiac surgery. The beneficial
ffect of beta-blockers has been demonstrated in interme-
iate and high-risk patients undergoing noncardiac surgery
3,4,38–40). Thus, the preoperative and perioperative use
f beta-blockade in patients undergoing noncardiac surgery
as become the standard of care. The magnitude of the
rotective effect has been such that the universal treatment
f all moderate- and high-risk patients, based on clinical
riteria, undergoing major noncardiac surgery has been
dvocated (41). The mechanisms by which beta-blockers
educe perioperative complications, including a decrease in
ympathetic activation, negative inotropy and chronotropy,
nd a subsequent decrease in myocardial oxygen demand,
nd neurohumoral effects have been reported to be inde-
endent of the statin beneficial effect (16). In our study,
owever, we were not able to demonstrate a lower rate of
omplications in patients receiving beta-blockers at the time
f surgery. Multiple explanations may be possible. First,
here may be a selection bias. Patients with known CAD are
ore likely to be on beta-blockade therapy, as it is the
tandard of care in this group. Therefore, the beneficial
ffect of beta-blockers might be offset by the higher likeli-
ood for complications in this subgroup. Second, the 95%
I of our estimates cannot exclude anywhere up to a 34%
eduction in the odds of complications, primarily due to the
etrospective nature of our analysis. Third, we were not
ware of the duration of time that the patients were placed
n beta-blockers.
The observational design of our study is a limitation. The
ack of complete ascertainment of lipid values and the lack
f information on the exact duration and drug dose of
tatins used are also limitations. However, obtaining such
nformation in a retrospective design would be very unreli-
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February 1, 2005:336–42 Statins Reduce Cardiac Events in Vascular Surgeryble. Furthermore, a much larger sample size would be
equired to investigate possible dose-response effects for the
equired protective dose and duration of statins or to probe
nto potentially differential effects of various statins; such
ubgroup or dose-response findings might be spurious. A
andomized trial would be indicated to further validate our
ndings, but our results strongly suggest that statins may be
n effective measure for reducing the incidence of acute
ardiac complications of major noncardiac vascular surgery.
onclusions. In a retrospective study involving over 1,100
onsecutive vascular surgeries, we demonstrate that preop-
rative use of statins significantly decreases cardiovascular
omplications. Although these data do not suffice to rec-
mmend the broad use of statins to decrease cardiac risk in
oncardiac surgery, our data create the impetus for a
rospective evaluation.
eprint requests and correspondence: Dr. Peter G. Danias,
ygeia Hospital, 4 Erythrou Stavrou Street and Kifissias Ave-
ue, Maroussi 15123 Greece. E-mail: pdanias@hygeia.gr;
danias@bidmc.harvard.edu.
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